Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
Anticipates FDA PDUFA goal date in late 2021If approved by the FDA for US market access, Libervant would be the...
News
Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™...
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer
Provides Compelling Rationale for the Upcoming Phase 2b Clinical Study in Patients with Poor Response to Androgen Receptor Signaling InhibitorsCALGARY,...
Corsair Pharma, Inc. to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension
SOUTH SAN FRANCISCO, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal...
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on...
Clubhouse Media Surpasses 300 Million Followers in Aggregate Social Media Reach
The Company’s Reach has Grown to Over 317 Million in Just 14 Months and Monetization is Now UnderwayLOS ANGELES, CA,...
Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile...
BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies
VANCOUVER, British Columbia, June 24, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an...
Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan
BOULDER, Colo., June 24, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer’s Association International Conference
Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s DiseaseMIAMI, June 24, 2021 (GLOBE...
BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing...
Walmart Extends Use of the Inovalon ONE® Platform
Retailer Extends Relationship with Inovalon to 2028BOWIE, Md., June 24, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider...
Major shareholder announcement
Orphazyme A/SCompany announcement No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a...
PRIMED, Traffic Tech and GlobalMedic Present: A Mask From Every Canadian to Keep Up The Fight Against COVID-19
MISSISSAUGA, Ontario, June 24, 2021 (GLOBE NEWSWIRE) -- PRIMED Medical Products partnering with GlobalMedic and Traffic Tech to donate 38...
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on...
VitalHub Announces 5-Year Licensing Contract to implement and use the TREAT Client Management and Care Coordination Solution with Family Service Toronto
TORONTO, June 24, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’),...
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Phase 2 trial expected to begin in the first quarter of 2022BASEL, Switzerland, June 24, 2021 (GLOBE NEWSWIRE) -- VectivBio...
Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4...
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
4D-110: Initial clinical safety data at both of the two dose levels in the Phase 1 clinical trial indicate that...